Human myeloid dendritic cells for cancer therapy: does maturation matter?

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

SKÁLOVÁ Kateřina MOLLOVÁ Klára MICHÁLEK Jaroslav

Year of publication 2010
Type Article in Periodical
Magazine / Source Vaccine
MU Faculty or unit

Faculty of Medicine

Citation
Web http://dx.doi.org/10.1016/j.vaccine.2010.05.042
Field Oncology and hematology
Keywords Dendritic cells; Cancer vaccine; Maturation cocktails
Description Dendritic cells form the connection between innate and adoptive mechanisms of the immune system. As antigen-presenting cells, dendritic cells are capable of presenting tumour antigen and effectively stimulating immune response targeted against a tumour. A number of preclinical and clinical studies document dendritic cells' potential in anti-cancer treatment. Increasing knowledge of dendritic cell biology is leading to improved methods for their preparation for clinical application. Unfortunately, there is to date no consensus specifying optimal conditions for dendritic cell preparation in vitro. This review summarizes the methods used for preparing myeloid dendritic cells derived from monocytic precursors while focusing on cytokine cocktails used for their growth, maturation, and functional adjustment.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.